» Sign in / Register

N6-Cyclopentyl-adenosine

CPA

Cat. No. Amount Price (EUR) Buy / Note
N-1078 200 μl (1 mM) 41,36 Add to Basket/Quote Add to Notepad
Structural formula of N6-Cyclopentyl-adenosine (CPA)
Structural formula of N6-Cyclopentyl-adenosine

For research use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at 4 °C
Short term exposure (up to 1 week cumulative) to ambient temperature possible. If stored as recommended, Jena Bioscience guarantees optimal performance of this product for 12 months after date of delivery.

Shelf Life: 12 months

Molecular Formula: C15H21N5O4

Molecular Weight: 335.36 g/mol

CAS#: 41552-82-3

Purity: ≥ 95 % (HPLC)

Form: solution in DMSO

Concentration: 1 mM

Applications:
Binding studies, physiological studies on cell cultures or tissues and in animal experiments.
Compound has highest activity to nucleoside receptor type A1 and a less extent to human A2A and A3[1].

Usage: Dissolve stock solution with aqueous physiological buffer recommended for displacement studies, biochemical signal transduction studies or animal experiments.
To avoid biological effects of DMSO dilute the stock solutions with aqueous buffers to a content of DMSO below 1 %.

Please note: Stable in acidic and neutral buffer solutions for one day

Selected References:
[1] Hasko et al. (2007) Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol.& Therapeutics 113:264.
Shenone et al. (2010) A1 Receptors Ligands: Past, present and future trends. Cur. Topics in Medicin. Chem. 10:878.
Goncalves et al. (2008) Presynaptic adenosine and P2Y receptors. Handbook of Experimental Pharmacology 184:339.
Wittendorp et al. (2004) The mouse brain adenosine A1 receptor: functional expression and pharmacology. Europ. J. Pharmacol. 487:73.
Soudijn et al. (2002) Allosteric modulation of G protein-coupled receptors. Current Opinion in Drug Discovery & Development 5 (5):749.
Hess (2001) Recent advantages in adenosine receptor antagonist research. Expert Opin. Ther. Patents 11 (10):1533.
Jacobson (2001) Probing adenosine and P2 receptors: design of novel purines and nonpurines as selective ligands. Drug Development Res. 52:178.
Merighi et al. (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. Brit. J. Pharmacol. 134:1215.
Klotz et al. (1998) Comparative pharmacology of human adenosine receptor subtypes – characterization of stable transfected receptors in CHO cell. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1.
Van Galen et al. (1994) A binding site model and structure-activity relationships for rat A3 adenosine receptor. Molecular Pharmacology 45:1101.